Overview
ISO 5840-2:2021/Amd 1:2025 is an important International Standard amendment that addresses updates to the requirements for cardiovascular implants-specifically, surgically implanted heart valve prostheses. Developed by ISO Technical Committee 150/SC 2 (Cardiovascular implants and extracorporeal systems), this standard amendment ensures that manufacturers, clinicians, and regulators have access to the latest harmonized guidelines and terminology in the rapidly evolving field of cardiac valve substitutes.
With a focus on practical and technical updates, this amendment refines the terminology, normative references, measurement protocols, and labelling requirements for surgically implanted heart valve prostheses. By maintaining alignment with global practices, ISO 5840-2:2021/Amd 1:2025 enhances patient safety, device performance, and market access.
Key Topics
This amendment covers several key updates, including:
- Normative References: Incorporation of ISO/PAS 7020:2023, detailing sizing parameters for surgical valve prostheses and requirements regarding the application of ISO 5840-2.
- Terminology Updates: Revisions such as replacing "supra-annulus" with "supra-annular region" to improve clarity and harmonize anatomical descriptions.
- Measurement Protocols: Updated technical requirements for pressure and flow measurements in valve testing, specifying upper frequency limits and measurement accuracy.
- Table Revisions: Revised parameters for cardiac cycle testing, including beat rates, systolic duration, and conditions (hypotensive, normotensive, severe hypertensive).
- Reporting Requirements: Refined expectations for reporting regurgitant volume, differentiating between closing volume, leakage volume, and associated differential pressure.
- Labelling and Documentation: Alignment of labelling requirements with ISO 5840-1:2021 and ISO/PAS 7020:2023, ensuring consistency in device identification and model description.
Applications
Implementing ISO 5840-2:2021/Amd 1:2025 provides practical benefits across the global medical device industry:
- Medical Device Manufacturers: Ensures cardiac valve prostheses meet the latest safety, performance, and labelling requirements, streamlining regulatory approval and market access globally.
- Regulatory Authorities: Offers a harmonized foundation for reviewing and approving surgically implanted heart valve substitutes, ensuring patient safety through adherence to internationally recognized standards.
- Clinical Laboratories and Test Facilities: Supports accurate and repeatable measurement procedures for device testing, facilitating compliance with updated validation criteria.
- Clinicians and Healthcare Providers: Provides clear device labelling and terminology, improving communication, device selection, and patient care management.
By adhering to ISO 5840-2:2021/Amd 1:2025, organizations can support product quality, reduce compliance risks, and foster trust with stakeholders.
Related Standards
Professionals working with surgically implanted heart valve substitutes should also be aware of related standards that form the foundation of best practices in cardiovascular implants:
- ISO 5840 Series: Comprehensive family of standards covering all aspects of cardiac valve prostheses.
- ISO 5840-1:2021: Heart valve substitutes implanted by any technique-General requirements.
- ISO 5840-2:2021: Surgically implanted heart valve substitutes-Main standard framework.
- ISO/PAS 7020:2023: Details on sizing parameters and application requirements for surgical valve prostheses.
- Other Related ISO Standards: Various standards addressing design, performance, testing, and labelling for implants for surgery.
Staying updated with these standards is essential for regulatory compliance, innovation, and optimal patient outcomes in cardiovascular device development and implantation.
Открыть превью (PDF)Cardiovascular implants — Cardiac valve prostheses — Part 2: Surgically implanted heart valve substitutes — Amendment 1
